Shandong Xinhua Pharmaceutical Gains Approval for Epalrestat Tablets License Transfer

Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) has shared an announcement.

Shandong Xinhua Pharmaceutical Company Limited announced that it has received approval from the National Medical Products Administration for a supplementary drug application related to its Epalrestat Tablets. This approval allows for the change of the marketing license holder, which is part of a broader agreement with Jiangsu Dongke Kangde Pharmaceutical Company Limited. The agreement involves the transfer of marketing authorization holder status and related technical ownership rights for Epalrestat Tablets to Xinhua Pharmaceutical, which is expected to enhance the company’s market position and operational capabilities.

More about Shandong Xinhua Pharmaceutical Company Limited Class H

Shandong Xinhua Pharmaceutical Company Limited is a pharmaceutical company based in China, primarily involved in the production and marketing of prescription drugs. The company focuses on developing and distributing pharmaceutical products, with a market emphasis on prescription medications.

Average Trading Volume: 2,164,457

Technical Sentiment Signal: Buy

Current Market Cap: HK$8.53B

For an in-depth examination of 0719 stock, go to TipRanks’ Stock Analysis page.